Physician profile
Tamara E Meyers
NPI 1659558112
$3,242.80
in general payments reported to CMS, 2019-2025
22 companies · $776 in 2025
The $776 reported for 2025 was more than what 76% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $626 · 2022: $535 · 2023: $508 · 2024: $798 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,060 · Education: $21.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,060.15 |
| Education | $21.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,242.40 | 2021-2025 | |
| Janssen Biotech, INC. | $500.68 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Ardelyx, INC. | $189.96 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $177.06 | 2022-2025 | Entyvio, Gattex |
| Gilead Sciences, INC. | $160.04 | 2021-2025 | |
| Qol Medical, LLC | $135.52 | 2022-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.03 | 2021-2024 | Relistor, Xifaxan |
| Organon LLC | $105.09 | 2021-2025 | Hadlima |
| Celgene Corporation | $101.43 | 2022-2023 | Zeposia |
| Madrigal Pharmaceuticals | $90.86 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $79.94 | 2023-2025 | Omvoh |
| Celltrion USA INC. | $60.46 | 2024-2025 | Vegzelma, Zymfentra |
| Daiichi Sankyo INC. | $42.06 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.32 | 2023-2024 | Cyltezo |
| Pfizer INC. | $35.79 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $31.09 | 2023 | Rebyota |
| Genzyme Corporation | $29.56 | 2025 | |
| Intercept Pharmaceuticals, INC. | $29.20 | 2022-2024 | |
| Nestle Healthcare Nutrition INC. | $28.73 | 2021 | |
| Pharmacosmos Therapeutics INC. | $17.74 | 2024 | Monoferric |
| Biocon Biologics INC | $16.84 | 2025 | Yesintek |
| Aimmune Therapeutics, INC. | $15.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Meyers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.